Payment overview · 2025
General Payments
$267.83
14 reported records · 3 companies
Healthcare provider profile · identity verified
Daniel B Levy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LUTHERVILLE, MD · NPI 1467470047
Verified facts
What the public records show
CMS Open Payments records show Daniel B Levy, M.D. received $267.83 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $192.28 | 71.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.23 | 14.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.32 | 13.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.83 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.38 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.32 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.86 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
136 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 741 | 213 |
| Amlodipine Besylate | Amlodipine Besylate | 489 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 118 |
| Losartan Potassium | Losartan Potassium | 464 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 92 |
| Lisinopril | Lisinopril | 306 | 84 |
| Gabapentin | Gabapentin | 305 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 285 | 59 |
| Lorazepam | Lorazepam | 256 | 66 |
| Omeprazole | Omeprazole | 256 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 252 | 72 |
| Eliquis | Apixaban | 250 | 50 |
| Prednisone | Prednisone | 244 | 158 |
| Celecoxib | Celecoxib | 234 | 72 |
| Trazodone Hcl | Trazodone Hcl | 234 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 69 |
| Alprazolam | Alprazolam | 203 | 40 |
| Furosemide | Furosemide | 199 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 48 |
| Metformin Hcl | Metformin Hcl | 185 | 51 |
| Sertraline Hcl | Sertraline Hcl | 180 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 59 |
| Simvastatin | Simvastatin | 164 | 46 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 161 | 128 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 40 |
| Allopurinol | Allopurinol | 152 | 44 |
| Cefdinir | Cefdinir | 146 | 109 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 146 | 103 |
| Synthroid | Levothyroxine Sodium | 136 | 36 |
| Clonazepam | Clonazepam | 128 | 26 |
| Atenolol | Atenolol | 120 | 33 |
| Glimepiride | Glimepiride | 118 | 32 |
| Meloxicam | Meloxicam | 112 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 30 |
| Pregabalin | Pregabalin | 110 | 26 |
| Azithromycin | Azithromycin | 109 | 77 |
| Montelukast Sodium | Montelukast Sodium | 108 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 23 |
| Famotidine | Famotidine | 104 | 36 |
| Irbesartan | Irbesartan | 103 | 26 |
| Mirtazapine | Mirtazapine | 100 | 23 |
| Bupropion Xl | Bupropion Hcl | 99 | 27 |
| Amoxicillin | Amoxicillin | 96 | 76 |
| Metformin Hcl Er | Metformin Hcl | 95 | 25 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 94 | 12 |
| Ibuprofen | Ibuprofen | 90 | 25 |
| Spironolactone | Spironolactone | 90 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 25 |
| Finasteride | Finasteride | 78 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 76 | 14 |
| Potassium Chloride | Potassium Chloride | 76 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Carvedilol | Carvedilol | 70 | 20 |
| Buspirone Hcl | Buspirone Hcl | 69 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 16 |
| Donepezil Hcl | Donepezil Hcl | 67 | 17 |
| Valacyclovir | Valacyclovir Hcl | 67 | 36 |
| Diazepam | Diazepam | 65 | 20 |
| Ramipril | Ramipril | 65 | 14 |
| Alendronate Sodium | Alendronate Sodium | 64 | 16 |
| Cephalexin | Cephalexin | 64 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 19 |
| Jardiance | Empagliflozin | 63 | 12 |
| Propranolol Hcl | Propranolol Hcl | 63 | 16 |
| Methylprednisolone | Methylprednisolone | 62 | 42 |
| Lamotrigine | Lamotrigine | 61 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 43 |
| Xarelto | Rivaroxaban | 60 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | suppressed |
| Ozempic | Semaglutide | 59 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 27 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 28 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 53 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 51 |
| Farxiga | Dapagliflozin Propanediol | 49 | 11 |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 14 |
| Nifedipine Er | Nifedipine | 46 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 34 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 45 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 11 |
| Verapamil Er | Verapamil Hcl | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 44 | 14 |
| Colchicine | Colchicine | 43 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Glipizide | Glipizide | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Acyclovir | Acyclovir | 33 | 14 |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Estradiol | Estradiol | 32 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Baclofen | Baclofen | 29 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 28 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 11 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 22 | 15 |
| Lactulose | Lactulose | 22 | 11 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Nystatin | Nystatin | 21 | suppressed |
| Zaleplon | Zaleplon | 21 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lamivudine | Lamivudine | 20 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Tivicay | Dolutegravir Sodium | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Risperidone | Risperidone | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 12 |
| Minoxidil | Minoxidil | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Cefadroxil | Cefadroxil | 15 | 14 |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Desonide | Desonide | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Asmanex | Mometasone Furoate | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Efavirenz | Efavirenz | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.83 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, MOUNJARO, QULIPTA, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error